Tesia Bobrowski

TL;DR: Results highlight the utility of drug repurposing and preclinical testing of drug combinations for discovering potential therapies to treat COVID-19 and show the combination of remdesivir and lysosomotropic drugs, such as hydroxychloroquine, demonstrated strong antagonism.

TL;DR: The main protease (Mpro) of the SARS‐CoV‐2 has been proposed as one of the major drug targets for COVID‐19 and QSAR models of these inhibitors were developed and employed for virtual screening of all drugs in the DrugBank database.

TL;DR: It is argued that, to develop effective treatments for COVID-19 and be prepared for future epidemics, long-term, consistent investment in antiviral research is needed.

TL;DR: The combination of nitazoxanide, an FDA-approved drug, and remdesivir, FDA emergency use authorization for the treatment of COVID-19, demonstrate a strong synergistic interaction and the combination of remdesvir and hydroxychloroquine demonstrated strong antagonism.

TL;DR: COVID-KOP can be used effectively to generate new hypotheses concerning repurposing of known drugs and clinical drug candidates against COVID-19 by establishing respective confirmatory pathways of drug action.